Topical niclosamide (ATx201) reduces <i>Staphylococcus aureus</i> colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double‐blind, placebo‐controlled Phase 2 trial

Abstract

These results suggest that ATx201 could become a new treatment modality as a decolonizing agent.